BioCol-VIR: Post-Vaccination Biological Collection
Study Details
Study Description
Brief Summary
Introduction: Vaccination is a powerful weapon in the fight against infectious diseases, which has led to dramatic reduction in mortality and complications from some diseases. In this respect, vaccination is a real worldwide public health challenge (WHO). Thus, vaccine research benefits from an exponential development of knowledge in immunology and biotechnology. In particular, the advent of recent tools ("omics", new cytometric assays) and the description of new categories of immune cells (Tfh, BReg...) have revolutionized the characterization of immune responses, particularly post-vaccination. To study of the immune response following vaccination remains essential in order to define the immunological correlates to vaccine protection. This response also varies according to parameters related to the vaccine (type, adjuvant, dose, regimen…) and to the vaccinated host (genetics, age, morbidity, treatment …). Analyzing with new generation immune assays, new data on immunological responses post-vaccination from a clinical cohort is therefore essential to better define these correlates.
Objective: To develop new vaccines (HIV, emerging infectious diseases) the investigators use a "System vaccinology" method to decipher the mechanisms of immune responses set up against vaccines currently being developed or marketed, specifically in specific populations (patients with primary immune deficiency, sickle cell patients, solid organ transplanted patients, COPD).
Method: Description of the genetic, molecular and cellular mechanisms of the immune response to vaccines recommended for adults, in particular influenza and pneumococcal vaccines, but also other mandatory vaccines (MMR,...) or vaccine for travelers (yellow fever, ...) as part of routine care in different population categories (healthy subjects, HIV+ subjects, COPD patients, …), using qualitative and quantitative immunological assays: transcriptional analysis of the dynamic innate immune response, analysis of the lymphocytes B & T responses (phenotype, repertoire analysis, functional analysis including T reg and TFH populations, antibody response), genetic analysis in the context of primary immune deficiencies) Conclusion: The data generated will allow the best possible analysis of vaccine responses according to vaccines and vaccinated populations, providing important information for the research developed within the department.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Change in transcriptional analysis, analysis of the innate immune response after vaccination [Hour 24 after vaccination]
Transcriptomic analysis performed from whole blood samples
Secondary Outcome Measures
- B cell immune response [at Day 0, Day 7, Day 14 and Month 1 after vaccination]
(phenotype, analysis of the repertoire B, functional analysis, antibody response, plasmablastic response)
- T cell immune response [at Day 0, Day 7, Day 14 and Month 1 after vaccination]
(phenotype, T repertoire analysis, functional analysis, especially of the Treg and TFH populations)
- Specific antibody response to the used vaccines at M1 [at Month 1]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years old
-
Informed and consented
-
Need to be vaccinated for routine care
Exclusion Criteria:
-
Person under guardianship or safeguards
-
Pregnant or breastfeeding woman
-
No affiliation to a health insurance scheme
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Pr Gallien | Créteil | France | 94000 |
Sponsors and Collaborators
- Assistance Publique - Hôpitaux de Paris
- Institut National de la Santé Et de la Recherche Médicale, France
Investigators
- Study Chair: Laetitia Gregoire, APHP URC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- K170603J